| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014 | 320 | 2014 |
| Immunogenomic landscape of hematological malignancies O Dufva, P Pölönen, O Brück, MAI Keränen, J Klievink, J Mehtonen, ... Cancer Cell 38 (3), 380-399. e13, 2020 | 138 | 2020 |
| Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target O Dufva, M Kankainen, T Kelkka, N Sekiguchi, SA Awad, S Eldfors, ... Nature communications 9 (1), 1567, 2018 | 128 | 2018 |
| Consistency in drug response profiling JP Mpindi, B Yadav, P Östling, P Gautam, D Malani, A Murumägi, ... Nature 540 (7631), E5-E6, 2016 | 95 | 2016 |
| HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ... Leukemia 31 (2), 301-309, 2017 | 89 | 2017 |
| Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization M Ammad-Ud-Din, SA Khan, D Malani, A Murumägi, O Kallioniemi, ... Bioinformatics 32 (17), i455-i463, 2016 | 89 | 2016 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer discovery 12 (2), 388-401, 2022 | 85 | 2022 |
| Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ... Leukemia 31 (5), 1187-1195, 2017 | 54 | 2017 |
| Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML R Karjalainen, M Liu, A Kumar, L He, D Malani, A Parsons, M Kontro, ... Leukemia 33 (10), 2548-2553, 2019 | 35 | 2019 |
| Hemap: an interactive online resource for characterizing molecular phenotypes across hematologic malignancies P Pölönen, J Mehtonen, J Lin, T Liuksiala, S Häyrynen, S Teppo, ... Cancer research 79 (10), 2466-2479, 2019 | 29 | 2019 |
| Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia BS White, SA Khan, MJ Mason, M Ammad-Ud-Din, S Potdar, D Malani, ... NPJ precision oncology 5 (1), 71, 2021 | 22 | 2021 |
| Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling D Brunen, MJ García-Barchino, D Malani, NJ Basheer, C Lieftink, ... Oncotarget 7 (25), 37407, 2016 | 21 | 2016 |
| Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022; 12: 388–401. doi: 10.1158/2159-8290 D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... CD-21-0410.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 10 | |
| FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML J Kivioja, D Malani, A Kumar, M Kontro, A Parsons, O Kallioniemi, ... Scientific Reports 11 (1), 23565, 2021 | 7 | 2021 |
| KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia D Malani, B Yadav, A Kumar, S Potdar, M Kontro, M Kankainen, ... Leukemia 34 (10), 2780-2784, 2020 | 7 | 2020 |
| High-content imaging to phenotype human primary and ipsc-derived cells L Veschini, H Sailem, D Malani, V Pietiäinen, A Stojiljkovic, E Wiseman, ... Leukemia Stem Cells: Methods and Protocols, 423-445, 2021 | 4 | 2021 |
| High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options … CA Heckman, M Kontro, T Pemovska, S Eldfors, H Edgren, E Kulesskiy, ... Blood, The Journal of the American Society of Hematology 120 (21), 288-288, 2012 | 3 | 2012 |
| Identification and clinical exploration of individualized targeted therapeutic approaches in acute myeloid leukemia patients by integrating drug response and deep molecular … D Malani, A Kumar, B Yadav, M Kontro, S Potdar, S Eldfors, J Saarela, ... Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 854-854, 2017 | 2 | 2017 |
| AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines D Malani, A Murumägi, B Yadav, T Pemovska, JP Mpindi, M Kontro, ... Blood, The Journal of the American Society of Hematology 124 (21), 2163-2163, 2014 | 2 | 2014 |
| Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia E Olesinski, K Bhatia, C Wang, M Pioso, SX Ng, XX Lin, V Sandhu, ... Blood 142, 48, 2023 | 1 | 2023 |
